Augmedix Q1 2024 Adj EPS $(0.12) Beats $(0.13) Estimate, Sales $13.471M Beat $13.367M Estimate
Portfolio Pulse from Benzinga Newsdesk
Augmedix reported Q1 2024 earnings with an adjusted EPS of $(0.12), surpassing the $(0.13) estimate, and sales of $13.471M, exceeding the $13.367M forecast. This represents a 39.91% increase in sales compared to the same period last year.
May 13, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Augmedix's Q1 2024 earnings exceeded expectations with an adjusted EPS of $(0.12) and sales of $13.471M, indicating a strong year-over-year sales growth of 39.91%.
Beating both EPS and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The significant year-over-year sales growth further strengthens the company's financial position and market confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100